The knockdown of FANCL display more significant sensitivity to cisplatin in A549/DDP cells, as opposed to the depletion of FANCF, comparable to that of the FANCD2, suggesting that the combination of the gene therapy by depleting certain FA/BRCA pathway upstream gene and cisplatin has synergistic anti-tumor activity against cisplatin-resistant lung cancer cells. Here, FANCL is linked to lung carcinoma.